Helen Dakin

Helen Dakin is a health economist specialising in methods for assessing the cost-effectiveness of healthcare interventions using randomised trials or decision-analytical models. She is particularly interested in methods to deal with uncertainty, interacting healthcare decisions and factorial trials.

Helen is currently undertaking a fellowship evaluating methods for dealing with interacting decisions in economic evaluation and health technology assessment. She has led health economic analyses of numerous randomised controlled trials, models and observational studies. Her ongoing applied projects include:

• Monoclonal Antibody Medications in inflammatory Arthritis (MAMA) trial evaluating whether biologic drugs for inflammatory arthritis can be safely continued in pregnancy.
• Trial of patient-initiated care leading to improved outcomes in rheumatology (TaiLOR), which includes a randomised trial and analysis of OpenSafely data to evaluate the impact of patient-initiated follow up.
• The KAT trial, which assesses the cost-effectiveness of different types of knee replacement component.
• The Supporting Women with adhErence to adjuvant Endocrine Therapy following breast cancer (SWEET) trial.

Helen co-leads the Health Economics for Clinical Trials and Patient Reported Outcomes module of the MSc in Clinical Trials and the HERC online short course Integrating Economic Evaluation into Clinical Trials. She developed and leads the HERC Database of Mapping Studies.

Helen joined the Health Economics Research Centre in February 2008. In 2014, she completed a DPhil at the University of Oxford on the optimal methods for conducting economic evaluations of factorial clinical trials. She previously worked at Abacus International and completed her MSc in Economic Evaluation in Healthcare at City University. She graduated from Cambridge University with Masters and Bachelor's degrees in Biochemistry.